Lung Cancer Clinical Trials in Beijing, Beijing Municipality
79 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 79 trials
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled215 locationsNCT06345729
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+1 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting
Phase 1Phase 2
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Lung CancerPancreas CancerThyroid Cancer+1 more
Sichuan Enray Pharmaceutical Sciences Company54 enrolled9 locationsNCT07433283
Recruiting
Phase 1Phase 2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
SarcomaCancerLeukaemia+2 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled1 locationNCT07026669
Recruiting
Phase 1
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
NSCLC (Advanced Non-small Cell Lung Cancer)
Peking University Cancer Hospital & Institute21 enrolled1 locationNCT06969612
Recruiting
Phase 1Phase 2
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.104 enrolled21 locationsNCT05276726
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Non-small Cell Lung CancerKRAS P.G12C
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Peking University Cancer Hospital & Institute65 enrolled1 locationNCT06869239
Recruiting
Phase 2
Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)
Stage IVB Lung CancerNon-Squamous
Cancer Institute and Hospital, Chinese Academy of Medical Sciences44 enrolled1 locationNCT06793813
Recruiting
Phase 3
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
Hansoh BioMedical R&D Company460 enrolled9 locationsNCT06498479
Recruiting
The Effects of Programmed Death-ligand 1 on Postoperative Pain for Lung Cancer Patients
Lung CancerPostoperative Pain
Peking University People's Hospital100 enrolled1 locationNCT06503432
Recruiting
Phase 2
Serplulimab Combined With CCRT for LS-SCLC.
Small Cell Lung Cancer
Peking Union Medical College Hospital96 enrolled1 locationNCT06295926
Recruiting
Observation on the Frailty Status of Lung Cancer Patients
Lung Cancer
Peking University Third Hospital200 enrolled1 locationNCT06448455
Recruiting
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Breast CancerLiver CancerColorectal, Cancer+10 more
Beijing Friendship Hospital2,700 enrolled4 locationsNCT06363123
Recruiting
The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy
Liver CancerPancreatic CancerLung Cancer+1 more
Peking University Third Hospital57 enrolled1 locationNCT06342323